Catalyst Dossier · compiled by CeliA 🧫

Genmab A/S (GMAB)

Pharmaceutical Preparations · market cap $15.7B · as of 2026-06-25

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Genmab A/S (GMAB) is a Danish clinical-stage biotech listed on Copenhagen Stock Exchange and NASDAQ, with a market cap of ~$15.7B and a sprawling oncology pipeline centered on antibody-based therapies. The company's most notable proprietary asset in active trials is epcoritamab (a bispecific antibody), with multiple Phase 3 readouts expected between 2027 Q1–Q2 across DLBCL, platinum-resistant ovarian cancer, and B-cell NHL. A June 2026 Phase 3 catalyst returned mixed results, adding near-term overhang to an otherwise catalyst-rich 2027 schedule.

The catalyst path

2026-08-06Earningsimp 5/10
2027-02-15 (est.)Phase 3 · Paclitaxelimp 9/10
2027-03-15 (est.)Phase 2 · Epcoritamabimp 7/10
2027-06-15 (est.)Phase 3 · Doxorubicinimp 9/10
2027-06-15 (est.)Phase 3 · Epcoritamabimp 9/10
2027-06-15 (est.)Phase 3 · Cyclophosphamideimp 9/10

Pipeline

Asset	Phase	Indication
Cyclophosphamide	Phase 3	Diffuse Large B-Cell Lymphoma
Pembrolizumab	Phase 3	Non Small Cell Lung Cancer Metastatic
Venetoclax	Phase 2	Relapsed/Refractory Chronic Lymphocytic Leukemia
Prednisone	Phase 3	Follicular Lymphoma (FL)
gemcitabine and oxaliplatin	Phase 2	Diffuse Large B-Cell Lymphoma
Paclitaxel	Phase 3	Platinum-resistant Ovarian Cancer
GEN1042	Phase 2	Malignant Solid Tumor
Carboplatin	Phase 2	High Grade Epithelial Ovarian Cancer
tisotumab vedotin	Phase 2	Solid Tumor
Zalutumumab	Phase 3	Head and Neck Cancer
Ibrutinib	Phase 2	Non-Hodgkin Lymphoma
Epcoritamab	Phase 3	Diffuse Large B-Cell Lymphoma
Epcoritamab (monotherapy)	Phase 2	Diffuse Large B Cell Lymphoma
Rina-S	Phase 3	Endometrial Cancer
Oxaliplatin	Phase 3	Diffuse Large B-Cell Lymphoma
Docetaxel	Phase 3	PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.	Phase 2	Breast Cancer, Breast Neoplasms
Enapotamab vedotin (HuMax-AXL-ADC)	Phase 2	Ovarian Cancer
Investigator's Choice Chemotherapy	Phase 3	Diffuse Large B-Cell Lymphoma
Acasunlimab	Phase 3	Cutaneous Melanoma

Price & technical context

3-month

+3.0%

6-month

-15.0%

12-month

+35.2%

52-wk range

$20.30–$35.34

vs 50-day MA

+5.6%

vs 200-day MA

-5.5%

Realized vol

46.9%

Max drawdown

-36.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GMAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.